Bio-Path expands global patent portfolio with new patents in Mexico, Australia, Japan

BIO-PATH HOLDINGS, INC.

Received newly issued patents in Mexico (IGF-1R inhibition), Australia (STAT3, IGF-1R, BCL2 inhibition), and Japan (liposomal formulation).
Portfolio now includes 5 issued US patents and 54 foreign patents covering 21 countries.
Expects six additional patent grants this year; 51 pending applications across six families.
Patents protect DNAbilize antisense platform and provide 20 years of exclusivity for new targets.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.